<SEC-DOCUMENT>0001193125-14-390718.txt : 20141031
<SEC-HEADER>0001193125-14-390718.hdr.sgml : 20141031
<ACCEPTANCE-DATETIME>20141031060834
ACCESSION NUMBER:		0001193125-14-390718
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20141031
FILED AS OF DATE:		20141031
DATE AS OF CHANGE:		20141031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		141184728

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d813842d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 31 October 2014 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOVOGEN LIMITED</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ASX: NRT)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(NASDAQ:NVGN)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g813842tx_pg003.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">31&nbsp;October 2014 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clarification of Capital Raise Option
Issue Announcement on 16&nbsp;October 2014 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;October, 2014</B>: Novogen Ltd today
advises a clarification of the Option Entitlement forming part of the current Capital Raise announced on 16&nbsp;October 2014 (&#147;Original Announcement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the clarified terms, the option holders will be provided the opportunity to benefit from a fixed option price determined by the 5-day WVAP for the
period 27/10/2014 to 31/10/2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Option price, along with the price of the accompanying Shares to be issued, will be announced at 9.00 am Monday 3<SUP
STYLE="font-size:85%; vertical-align:top">rd</SUP>&nbsp;November 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen CEO, Dr Graham Kelly, said, &#147;In response to enquiries by potential
investors, the Company has decided to provide greater certainty over the option term. Rather than a fixed discount term and floating exercise price, the options now will have a set exercise price&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen shareholders on 13&nbsp;August 2014 approved the issue 80&nbsp;million additional shares (to be issued at up to 20% discount to market) and
80&nbsp;million options to raise up to a maximum of A$10M. The current Offer is based on this approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offer will take place via the ASX Bookbuild
facility and a panel of Australian stockbrokers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An option will be issued for every share on the following terms: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">It may be exercised by its holder at any time up to the first anniversary of its issue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On exercise it will entitle the option holder to one share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The exercise price will be 90% of the five-day VWAP (27/10/2014 to 31/10/2014); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The options may not be traded except in accordance with section 708 of the Corporations Act (for example to other sophisticated or institutional investors). </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian
drug-development company whose shares trade on both the Australian Securities Exchange (&#145;NRT&#146;) and NASDAQ (&#145;NVGN&#146;). The Novogen Group includes a New Haven, Connecticut-based joint venture company, CanTx Inc., with Yale
University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9472 4100 - F: +61 (0)&nbsp;2 9476 0388 | www.novogen.com
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP
compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular
drugs, result in comprehensive and fatal destruction of the cancer cell&#146;s cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key
clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further
information is available on our website <U>www.novogen.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information please contact: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Novogen Enquiries</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><B>Offer Enquiries</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dr Graham Kelly</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Cristyn Humphreys</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CEO Novogen Group</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Operations Manager</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Graham.Kelly@novogen.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><U>Cristyn.Humphreys@Novogen.com</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">+(61 2) 9472 4100</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">+(61 2) 9472 4111</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Media Enquiries</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cristyn Humphreys</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Operations Manager</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Cristyn.Humphreys@Novogen.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">+(61 2) 9472 4111</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9472 4100 - F: +61 (0)&nbsp;2 9476 0388 | www.novogen.com
</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g813842tx_pg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g813842tx_pg003.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4`#F`P$1``(1`0,1`?_$`,,``0`"`@(#`0$`````
M```````("0<*`P8"!`4!"P$!``$$`P$!``````````````$%!@<(`@0)`PH0
M```&`@$$`0(#`@@)#0````$"`P0%!@<(`!$2$PDA,11!(A5A,E%Q@4(6%Q@9
MD:&Q4B,D>#D*T6(S0R8V9H:FMSA(6!$``0,"!`0"!`H(`@L``````0`"`Q$$
M(3$%!D%1$@=A(G&!$PB1T3)"8M(C,Q06P5)R@M,551=3DZ&2PH.C)%2$E"48
M_]H`#`,!``(1`Q$`/P#=9W,V?J6G&M&5]A[@"+EM0JXJM`09URH+6NZ2BJ<3
M3*HT$3%4,M/6-ZW0.).ID4#**B':F80H^OZS;;?T>?5[K[J&,FGZSLFM'[3B
M!X9\%>W;K95_W#WE8[2L*AUU,`]],(XF^:60\/*P&E<W%K<W`+^>A)^Q+V$S
MLI+6!]NULJP?3TK)3+J,K^6K7#UV-<RCQ9ZM&0$.S?)M(F$CS+^%HV2*4B*!
M"E`/CFF=YW+WE=7+YVWT\;7O)#6/<T"IR`!H`O8"R]W?M!;6D<3]"TZ1[6!I
M<Z%CG$@`5)(Q.&).)-2<2O1/OWOZ8JI?[<VV`"JB=,!+FVZ%,F8Q1+Y""$EU
M*<O7X$/D!Y\?[B;U!'_L;K`U^\=CX'')=D^[[V=QIM_3*EM/N&8'F,%NO>EC
M>I]NMJ/&(9`G#S&>\$.V6,<ONWBX*REG.W9>:FY)=AVE,<UZ@$>]RI\@>5:/
M`^```#:_MWNIFZ]NQW+W5U"$!DP.?4,G?OC&OZW5R7E][Q?:T=L=_2P:?%[/
M;E\#-;4^2S(2Q#$T$;C5H.4;V#&A*M^Y?:P"G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(M(?_`(A?=<^;-B(G46D2PKXWUN<I
M2V1BM%C?:3^;9F-3528N@(8".$<<UM^5$I3!_HY%^Y`?S)%$-8.]^ZY)[UFU
M[5Q%O#1\OTGD8#Q#6GX2>2]/O<R[7QZ1MN3N!J+`=3U+RPU&,=NPX$<C*\%Y
M^@(_$+7L$`*4"I_*?7KU_P"=^(<U\=DMYR```WY*_?PZ\^M0&UX(K"_5MNFO
MHKN!1\CS,BNSP_D15EB_.;(HB+4*E.OB)0EQ51`#=SF@6%PF^[BAY!9"Z2#_
M`*3F2NUFZG[<W)'%,2-.NB(Y!P%3Y7?NGUTJ.*U[]Y#ME;]Q>WES%$UHUNS!
MGMW'A(P5+:\&RMK&>`):X_)%/Z/I#D4(11,Q3D4*4Y#E$!*<A@`Q3%$/@2F`
M>H#S=->+Y!:2UV!"\N%"<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G"+36_P"(VTI&AY+J&\=#AQ)6,HJ16-LY$8-Q*A%WR/:`UH5U
M>^(H$33M4*V_27*H@'^M,6O<(G7$>:X=\-IEW1NJT::4#)J#E@QWK'E->(;S
M7I![E_=-L]A-VUU1_P#S-M66UJ<70O=62/Q,;W=0^@^F3!36>Z"`F2*("D0`
M/WA_"/\`,_C#FME*\5Z#$.!+&FL8QK^A?GU#GT)#FJ%:QZ<-)%=T]Q*ZK:8T
M7V#M>UH3*>5161`\?.2[=ZLOCC'SCR%,DN6QS\89V\1Z_FC8]8H_"@=<M=H=
MI-W!KO\`,+MO5I]G1YY.?7R-]&!)Y@4XK6#WI>Z@[?;#DT^PEZ=PZD##`!\I
MH(^UE\!&P^4_XCF>--AW9KW!Y6H^>+]0,!53$%EQO1'Q:J%GN3"W/Y&;M<2*
MB%J5CEH&V0D=^@Q\F`M&Y@2,94S<Z@'$AB=/1'2-B6]U8,N=1DECG>*]+>G`
M'+-IQIFOS?[U]Y._T?<5QINW+:TN=-A?T"202=3W-P>X=+VCIZJAN&(%>.&#
MO[Z?;H/WL>:Z]/V061^O_N*/*D>WFE$49/<=?"O1]56I_P#4N[?Z?IWP3?Q5
M:%ZX=_9K;]MD*H90AJC5<M49VVF&T=3TY5I!6.@RO1NSF(YI.R\U)`_AI5([
M:0#SF3#S-SE`OD$H6=N?;(T+V<D#W20.P<32K78D#`#`C+Q!6=.T'=X]Q?Q-
MCJ<4-OK$(#VMCZNE\6`<1U%QZF//FH?DN::#%6B\M%9Q3A$X1.$3A$X1.$3A
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MF-90('</QU$0#GR9V4WR74=';M;E]\S+X5W)/>T[+AE8]1>7TR]C+GZ>A;`E
M$H(^G?U>1F/UE8QMMQL*[?+V)W&N&SQ1OD^VQJ2<TNSD6X`+Z"PQ3$TFC98I
MCHJO42*$Z`Z'FWW9W83-%LH-/D8'B$B6X<!@YY.#:\1@&\BUKCQ7CU[[WO#'
M<5W>:U92/8R=CK/3FXM<V(8RSTS:X]1<,B'.B;\VHHZ:-2M$2-0$YP2*'<JH
M83**J#U%150XCW**JG$3&,/R(B(CS:=@8UE6\>"\<WN=([J*]KL+^(?'\?'6
M6X@"JXT65\#9LG]<,W8]S?72N%S4N1,E9(=L?M&R4:5`K.V0*H?NG4<QIA6;
M]P"!':")^G4H<I>K:;#?Z7+9](+Y!4GB#F"/0:%7AL3=5UL_<]KKMN3]C*.I
MM:=;#Y9&']IA('(T/!;N%/ME?OE4K=VJDDA,5FVP<78H"4;&`R#^(F&:+]@Z
M3'\`5;+E$0'Y*/P/R`\UZN();6=]O,*2L<6D>(P7J/I>I6FL:=!JM@[KLKB)
MLC#S:X5%>1&1'`U"['SXKOIPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(OD6"?AJK!35GL4BVB("O14A-S<J]4!)I&Q46U5>R#YRH/P1!JU0
M.<P_P%Y](HI)Y6PQ"LCW``<R30+JWM[;:=9RW]Z\1VD$;GO<<FM:"YQ]0"U*
M<C^T7;^ZY%NUJQWEEU0<<2]A?*T&GH5*HO%(FHH'!K!B^=RD0^?+2DBQ0*Z=
M"=00*NL8I0`H`',V:5LW1_Y<UMU$QUYAB>K'F<QQR\%YX;D[Z;]O-<N+K2]0
MN+;3GRN]G$T1!K&5\C<8W$D-IU$DU=7$KJ']XYO:(=!V%DP`1$`,6ET(#`'X
M=>M<YW?RGH(.%M%E]+ZRHG]Z.YG]8O/^#_!78<J7>[;G:TM,QW&=5M.?=.Y&
M1A,G)`DA'I6[!.1Y)%W#9*8U]CX(MO+5299`RE%6C=/N:H>1;KT2'G1M8F:#
MJWX2)@BTZ[Q:!C21K0'-QQHYHZF@DXAP&=%7]<U"^[E;'_GMY,^?<NC'HGJ<
M9+25Y='-TM`;U12N,<KFM'D=&YP%*J"!#@<H"!N\#`!@-]>H"'4!`?H(=.7:
M2VH?D",/0L'TH:',+S^G(ZFD9HN5C"SUIF8*I5.-6F;;;9N-J]<AD"B965FI
MQVFPCFI0^A2&77`3F'X(F!C"/0!'DSW#+"!]U*YH@Z#CRH,_0NYI>GW.JW\6
MG6;'/NI9&M8T9N<X@-:/$D@*R_(FZV;=4GE:U7U9R-!MJ%KY4V>/[;9IJJQ=
MU4NF6B/GLID*2AW<X*IHVL0\V_48,VR/1,O@/TZE`O+%L=L6.LEVHZG&\/E)
M<WS%M&$#H!`^=0=3JY$TR``V"U/NWKW;QL.S=I7$3[/3XA%*]S&2"2XZG.G=
M&2*"(2.,<8&!:SK-7.)/0`]I^_W<(#EZE].GP/\`5%3OD>GQ_P!5SL_D/0RQ
MI/6TUQ\Q."I9]X_N0*@36Y_W$?Q*R[UD>PW)V<LD6W">QUF@IRXR\=_2C%4[
M%5F,J:4@UAT.VU5)RTC#`U=231`22#8_:"AVY7`"(@D7EH[LVK#HT;;BRJZ"
MN.9P-*''D</6%FSLMWHU7>6M2Z%N=T?XN2/J@+6M8.IE2]A#0*ES?,T_0<,*
MBMXG+"6SZJ:>^VS%4'O@]T=M&+K_`%Q=M>X3&#?-KUY!*8X7OUJIS>VU.N.4
MTG'ZG'.;**PL6GE`!4=%#\O:;J$5455LO)4J&NBFY%=WIP8KG*KT6RX[C$LB
MY$QV->M;V*?RHN\>6)Q7G4I]Q#*K,P9RBB'E1)W>0A!Z&^>0#4511TSG[6L<
MTG+T_KIKAA+-6[6?:>L@A?*7@"$8N:KCAPJIXSL,A9/G'3.I5N52`![F_>N*
M1P%-<R*GY>*\E%5B-S[DSX?LL%&[OZ/;.Z:TJSO6,5#Y=MK6N9)QDTE'RYD4
MV]JLE`=/$:ZF!2]W4`<K`4!,9(J914XKS2JF7F[>NB8/S5IUC&6JTM9*1N=/
M3%2H6;*U,0KZBP=J1AF,Q5(J7(18[MXA?$I)$D:Z;"=(XB8P_D(<P":%*J<W
M)4J&N<=R*[AO975C5EC1;+D+(^STE=%T`KKZ):,<:T*@124G8\BW+]06*Y-!
MD,M]NV30(91PX*8A1`P`!HKC1%AC9_V@8EP+E,==,9XVRWMEL_\`IS>5>8.U
M\KA;+)U-@[\8M7N1[0X61KU$;N$E"G`KE11P1,Y%%$B)'*H(GX5!-%'F>]PM
MXPJZCIC<+US[9:S8G>N4&3W,*PTW+%2K+AVY3;MEK66@R#A>&COSB8ZG<HO\
M=$D51$`XK3/)*JXFA7VF92I=8R+CNS0]RHUSAF5@JUH@'B3^(FX>12*LT>LG
M20B4Y#D'H8H]#IG`2'*4Y3%"5*JYS%[>\7U[*]EP+J_@O.N\>7Z.]_3[Y$Z^
M5QL^H]'?)+"@[C+-DJ463KS25:+!V*)I`LBFH`IJ+$4#LY%>"BJ^IA[V29HN
M68J)B/,/K/W-P.ED29)!0N1I"%JU^QQ!O#-7+TSR]V6K2A&E1A4T&I@%RH*P
MBJ8A`3$3?"N-"$JNU[>>QQYK%L+C/6>FZN9BV3R9E'&LYDZ#B,4R5/:NDX>O
M2S^,E6YFMGDXT5EVB4>=P<Q3@0$A``ZF'IP2E5T:F^QW9JSW6F5:5]3FZ=.B
M+1;:]7):Z3KW%(P--C)J5:QSZUSI6EM6>FA:^V<&=.@1(=7PI&["B;H'%3R2
MJ^WO+[5<=:)9EQOBJ_8CR-<8NZT]+(%CO]/7A5(7'=-3N2-0F)^PQKM=.379
M09E@=+G2`">(0*!N\0#BJ5HK1(J4C9R+C9N'?-I.(F&#.4BI)DL1PSD(V0;I
MNV+YHNF)DUVSMJL51,Y1$#$,`A\#R5*A)B7>FK99S_ME@!ACRUPLOJ?D3#F/
M)VR2#Z&6A[F[S$$3^GRD`@V7,^9-((TN7[DCDI5%`(82=?CK%5%5"'W+;/C7
M*;`:IU%^4+!E-JG8<G*-E@\\5C5@^`&,*L*9N]%6[S3,4SE'M[V#1<H]2JAU
MR!LC16W4C]2GJ(X\&>GYQ]0P'B3R6KGO);Z?IFF1;.L'@3W0$EQ3,1@_9L\.
MMXZG5QZ6`9.JM=LI"(%%(H``DZ%*4/CH`?'0`_@#F8@YKPU[!1E*+1S$GS9E
M<O."Y++F`,Q)X$R]7<B23$9ND.&TE2,MU<Y!6;6O$]Q1_2;E$N6O4I'1VC)4
M'K<IO@'#8OT`1Y2]9TYVI69<P^SN(J&-W)[<6GX1CX$C(J[]C[B&V]>CN)FF
M739>J*XBJ0);>4%DK#2F)826DY/#7`@@$<NP&#Y+`F7+)CJ&;6&Y4<4(^VXN
MNL'"2\U&6K&%L0_5J;(IR<>R<-5WB$<H#5R`&Z^=`QOW3%$?GI6LLU"U]M<F
M.&>M'-)`Z7-P<VA/`UIX4*J&\=BZAH6NRV6FLEN],(;)!,QCG"6"5H?%)5HI
M4L(ZAP>'#@L/@RFQ^E6NH#_"-0LHA_@_2^5+\5:?/FB+>0(^-6M^7]=_Z.Y_
MRW_54O=?2.\#XUR-N%/QSJ.N$8J_PIJY!3T:O'/93+%JB5$;;DDD9))H/%HS
M%]5>*'16!(4A>JB7N[REY;FH/M-1O8M(MR3;$]<QK4=#35K*C_$<*'Z(=S62
MMIV,VSM$N]\ZDPQ:FWJM[%CVD._$2,^TG`=3"VA=U--*>V?'CY2%#AHCX$"$
M%55PL83*NG+@YE7+IVL8RKITY5.(G6<.5SF.<YA$QC&$1^1Y<S&O8VD@H5B.
M20RR%YS)7,<O4.O^;T'_`!]>?5KA0QGYR^)P-5]NJV^SX[M]1R52G?Z?;\?V
M.,ME:=_/C_4HI8%19N@+T%2/E6W>U<D'J"C=8Y1`0'G5O;.&^LWV4E'2EI%.
M8(R55T35KS0=5@U:P>67,$K7M=R<TU!X5',<14'`K=JU\S75MB,-T',5/5*,
M3=8)M(+,O*11Q"3*8"UGJ^^[!'L?0<NBLV4`>@B*?<'P8!YKQJ=A)IM])92Y
ML=@>8X'UC_3@O4S9VYK3=^W+77[2@;/&.MH->B082,/[+@0*XEM#3%:WMDUB
M7W'W#]X.#XI\,/>V[;6+(N&[*F<47=2S)1ZFYFZ+-,G0"!F)G$BS!FNJ7Y!J
MY4^OTY3L:E7)3%77>M3;%WN#JC2;_:VIH;,5,=2>(\_55P'BD*QF?'2I(.Y-
M7K0W11J$LLDG(HD$.A47A2@(]HCR0:A2,E3AHCG>:UE]$FTF<*R<4K11LB;5
MJU9R4.HL;3/Y+5JU;D1#N()@C9R<;N!`!`1!/IUY`P:H&55;IZK=:JAK-I#@
MV"@F:2ULR)1ZYE[*EL7("D]=<B9(AVEKG9>?DCF4<R+AHI*@T1,<XE*B@7M`
M.H]9`H%(4TLKXLHN;<;W3$V2X!E9Z+?J_(UJR0K]%)9%U'23<Z!U$15(H#=\
MT.8JS9<H>1NX3(H00.4!"5*U'*U1,A9(]1FTV&F,G(V;+'J7W!LU@PM8G!#+
MR1ZU@^QDLC&.;")G3P"MZHYE_$B40ZMRH-2]"EZ\XYBG)<>"VO=<LR0FPV!,
M.YRKJB)XC*V.*E>&Y$%`63:K3\,T?/X[R@4I5#QD@HJW.(``"=(>GQSD%R5+
MF,,CI9`VI]I'LN7;$EJ?J'C>R:GZZ+/$E'<8L]Q!6Y"\9IF(TY#]HHS60U&[
M,YT13.9N4Q#AU(4P\1G517CP4A_2-@R+H.DM*SK."G8,W;>+/]ALRY!>D!Q8
M+'+WN2?2L)%.Y)4OW9XZO0SA---`3"D1PHNH4`\@AR0@"MILM:K]RKTW4[7#
MQUAK-EBGT'/P4NU1?1<O$2;91H_CG[-<IT7#5VV5,0Y#`("4>2I6J1C_`#!=
MM!-.O==KM0)F9"/U'RBTB-=I%=V+I]4(/:!08:LLVSDZA7#<:T_=??%.!^I%
MU3*%_/U$>.(J%'!7Y^NK6&@ZF:@X6QA1X9LP>N:17+=?YH4DQF+AD2T0S&7M
M=DGWP"=:0?.))R=),3G,"+9)-(G0A"AR0*(,E-_DJ50)M]D?'^(O>!I%D/*E
MZJ>-Z)#:?YQ9REMNT_&UFNLG<M*69I&MG<Q+N6C!!5ZZ$")%.H`G/T`O41Z<
MCBH-*U5I=+WOTIR/;Z_C^@;8:\W2\VQZ:-K%1K&7:--V*P2)&SAZ9C#Q$?-.
M'TB[!HU54\:1#'[$S#TZ`/%0E0JM-SJ#6LO^Y;5/#=V9A(TC*^B>T-%MT<8"
M"#V$G&=G07*3R%,4KEJH!'"!^@F1<)$4+T,0!!Q3BLS>HC)UOI5?S-ZZ<URR
MLAFG0ZW%H\%*OCF*ZR'KG/\`DD\)WUD1P(.'#5*`4+'*B4O8@5%N01`YA(4.
M2!82TZ_WC'N$_P!I32C_`"TS@9E3Q7T_<[K$=TPK&W-1CN]]4VK*BY>!N014
M7I[I^8*C:%@*'R6L3<BHU<''Z-GQ3#T*B/,B[&UAD+GZ9<'R.Q9XU^4/]H>A
MRU.]Y;9$UY;0;RL&.<8@(KBG!M?L9*9TZB8W$?K1Y4)-`?7O[EE!^3CU*(?C
M^T.G[.9=#&QM;%#BVE5I37''@N3G!<EE#!6%YO8W,M&PM`N!9$M#]1Y;YGX*
ME5\>PH%>W*Q.53F(DB#2*`4D!,8H'=KI$Z]3!RF:M>-L-.EFN@3#3R`9N><&
MM_>-!\)5V;*VY<;IW';:5;D,:]]9)#@V*)OFEE<>`C8'.](`J*U4KLW^P#,J
MN3YF`U=RC8\4:\X^91F-<4U6KLZ\$:[K=);?HJ=H,I*0CYXH:P+-S*H`*G0K
M,$0$.[N,:WM-VE8NM1+K#&OU-Y+GU)S=B<CPR]2R;NGO3N2WU9]CLF[DL]K6
MS6PV\;6L^ZC`8UQZFN/4^G6>50,P2<5COGNW_P#IO(@?M^UIWQ^W_NQ^'.]^
M3]"D\C86-)XU=\:MS^]W<YN/\UN/]6+^&LCL,@7_`';PO?\`&V4;/(7[9'!?
MZQG/!5EE$8Y":NV/DV+5ME[%P$BVL<R=R,=',TI*/*")EU1)V`/1,W7I#3K7
M;]Y%-8XV,CA%*#DUY)]F_'@22P\,6JN_F+4^Z.VKK3M>F,^Z+!K[JU>>D.D@
M:T?BK>C0T$M8P7#,"3T2#T0%:.$G;9%T@(&2<)D5(8/H)3E`P#_*`\O,N+L2
M:K!I:6$M.87./=U#I^[]#?Q#^W@D,:9#F,E&>"\V[&5EW\77:W'KS$]89>-K
MU>AVI1.ZEK!-O$8Z*CFY?D?(Z?."$Z_0H"(C\!SY7$K(H/Q\QZ9.DD<,AG^E
M=JPLY[^\CL;9KGSR/:T-&))<0``.9)`'B5NBZ<:XP^JVOM&Q''^%>88M59Z\
MRB(F,2;OUA$LA:Y-,3&-T;&D3BBW`.@`V13#IUZ\U[UK43JFH/N\F$T;^R,J
M^)S/B<RO4'MSM!FR-IVVB.(=>T]I,X9&5X'4!GY6`!C3A5K0:"M!67HF`?WP
M7MW'XZ_:ZUA_Z.><I/SE?`K4U7A8Q5]>/M9B;>DF,=JY[0%F=5M?8?PPM#W#
MJ[50("<63'_0-"Y6AU/`H<1)YWJJRANH(<9'TJ<BHM:)Z_S>R7HOVGP+!HG/
M:[MD?;!G6F?[AW5N@<E.++6(XXB4PD^^GX1L@8>G4`./`R16K^I[9^H;,Z3X
M:<1;U!KD#$=-KF&LPTARMX[+1[[CN+1J;UG8(M8J+Q@:83A/O&YCIE(H10Q2
MB)DU`*!J@4W,PY=Q[@7&5TR_E2R1]2H-!@GUAL<W).$6Z*#-DD8Y6[<%E$P=
M23];M0:MR"*CAPH1,@"8P!R5*J(]*N(9B>U5SSG#*E3=PW]O+/.7<W_T1F?-
MY#8JOBBD95T'B"Q4U2)3,.JY43$0`562R!_YW('-0%$#5':R4T(]?7L<P)8W
M3A7(WKLR7D/'>)4%UD0>3L1F:7D%M="QB)TW)G(.[-,G$H`0Z9$""4"^-$1Y
M`P"@<E9WJMHZXQAZM8K4&9\"5\OV!KHTR3)NQ,4[K+F8X*7E[=)2SA`ZBK@\
M?9["*!C@<X^!J4I1$I2\D#"BG@L6>C[/T?>M.:[KA:O%7<^:;NY'`>7,>ONU
MG8(C^ATJ^C:U/*1JJAG)XV6B42(BX`/&+ULN4/@"B8,E*MUN%OJV/ZM8+O=I
M^*JU1JD2]G;'8YMXBPB8:(CD#N7K]^\7,5)%N@B01$1'J(_``(B`<E%JTXWP
M)?=]],_<CL528::19[N9/)9-9XY^V,RD;C4=:7:CVCRS9!1/S'1M\NP59-RB
M0.\Z/3KU$>G'$U7',*[3UD[<T#;[4?%=MK$J@6ZTNIU['N7J4Z7*2S4;(=4B
M6T+,Q\]&*`F\:I2B[`SMDJ<A2+MU0Z#WD4(21BI&5%A[VJ9QS+A,^BO]4%_E
M:(&2-Z,*8WR$$6SB'86K']B>.TYVK/QEH^0^W829"`!SH>)<.GY5"\%#FH[;
M74BFY)]Y>D%)R'3JQ?:;*:=YT=258N,!%V:`=N8Z4LKE@Y=1,PU>,%5F;@H&
M2.9,1(<>I>@\<4XJV:KZA:HTBR0UQIFM&!:G;:X\&0K]GK>(Z'"6"$?"@LU%
M[$S$;`MI"/="V<'3\B2A#=AS!UZ"/%`IHJP,_P#^_JT%_P!DG8?I_(C:/^7C
MBH^<OSV?5N:U1S[KM[6<=L'!X_$;UGA';^&B$3?<VW6O($PW9(61XBF4$GCG
M&EB>E<IG5ZF+Y41Z@FAU(/-"L9Z?3D&EO?[?;N>78%J#C,VE-[2L@N4PB#U$
ML54ITU@*]$?$,6$2B9?R]>WQ@(\<4XJ^^Z4^NY"J-FHMNC$)FKV^"E*Y8(IR
M7N1?1,PS68OFYOQ()VZQNTP=#$-T,40$`'GWMYY+6=EQ":2L<"/2/T<QQ"Z.
MJZ99ZSIL^DZ@P/LKB)T;V\VN%#3D1F#F"`1B%IXY!]?^VN-\@7*BP6"\EY"J
M]7L4C&U2\0$4TD(NUU8%//7Y<BY'Q1(\5BU4BNDS%**3DJA1#XYG?3-S:5-I
M[99)8F7)`P=(QM.8(+@<,O'->:NY>U>\M)UVYTZ'3M0N+>*5P;)%:W$D<C:^
M5[7LC<TAS:$@&K22TXA=0'3O<@.H_P!E?,P]/_#B'^+_`%_YY4OYMH^?XRT_
MSH_KJA#8&^/Z-J__`(-W_!4A%86PZ0ZH6D+A"O:3M?N2K)4J/@9%1NE:L6Z[
MUEQ]M8W[E)JX64BI*Y.W!T_WNION4/H=L<.6U*Y^OZXTP.$NFVCA0M(+'3$8
M4(P=T`UJ*@$CFLEBUF[:=O)FWL;X-VZZTQACP62PV#3YRYC@'L-P\%E'!KN@
M9"A)KO;H)HH)HH"4B*)"))IE#IV$(7H4.GX``!R]:=!`>/M`,2L"EW6:\UR]
MH_YPC^P?I_EY)<",0***+M-"OUIQ-D"E99HRI4;7CJ>:V.+!4XE:R2;?N3DX
M-^!!**L9/Q2JS-P3Z&26'\0#G5OK6UGMY+"Z;]G,PT`SQX^D9@\"JUMS6[W;
MVLVVM6#J75O,UXY>4XM/-KA5KAQ:2%*+.VM%NG;JWROJ]BC(.2,!YT@VF6:,
MMCZIR]K:T9[8G#@;?C.9&%:.B1<E3[,FX1(@H!!*@)2@`]@\MG3-?@M&?@-6
M?&V[B)8XN<&U(R=CP>T@^FHS!"R9NWMSJNJ:B-<V3975UMZ_C;<1>RC?((?:
M5Z[=Y:"`^&0/9CB6!KLB"<.#K-M&!_\`XQ[`B``(ATQ+<^@CT_'I$\K`US1Y
M82?Q=LS'C(VI'PJU/[8]P0['1M2/_;R?55GGJJTDOJ^:I'.V<<:W"@Q>)2`V
MQU7K_6I&N/YZ^3315-S:F\;+MF[A6-J<.J9-!;M[3/7?<0>Y`>69O7<EM/:,
MLM/D8\.'22T@T:,ZTXNR'A59\[#=IM9M-Q.W)NBTFMHK/&)DK"QSY7"C7`.`
M\L8J[]LLQP(.R-S%2W/4.<-Z7T3"VT>S^U<#;KI+W#:=/'Z=MK,TM"GJM9#'
ML2K$QXU9-E$M)5,9!-43K_=.7'Y@_+VAR`*&J+MFW.JF.=RL*S.%<E.IZ&8.
MY>O6BN7"I.6;&Y42YU.5;S%=MM3D'[&1:LI>/=("F(G14*HW653$``_4)1?(
MTQU(JFE>&CX:J%TNN0&#F]7;(+^T9`6AE[(_G;Y,'FY@7"D%$PT?X0>*").B
M('$1$3"(C\%`%`HIYX]2^*<@YCGMD=?LQYLTNV"M9P5N5\U]L36-@;XZ,J55
MQ(7K'TLT=UVP2#D2]55"_;E<*CY5RK*?FY%.24718STYUG(5JK]HW;VTV8WF
M9U"4:R]8QOE>?AZIAMN^9F*HW=SF-:*PC8RR.4U"!U%PKX5B]2+IJE^`4KFE
M%<<S9M(YHUCX]JV8L&+9!FR9,T$FS1FT;)%0;-6K9`I$6[9NB0I"$(4"D*``
M```<E2JNLX>IG!>=MIS;0V&_97A5YJQX4MV1L15^6@D,691L6`GXOL>R5RC7
M4"ZF5U&/C13."#Q$!*CU+VF45$\4445IW)4JL[:#U<X:V!RF78F@Y!R[JKLX
MG'$C%LY:\6D*E.65H@FFDU:W^!5;N8.Z-D$4BD$5B).%4B$346.D0I`BB@BJ
MP4MZ=5\LOXY'=3>O;3<*@Q+YA((X?M4_7\:8MFUF"GF22NM;QU'1REI;^4`'
MH9=NI\=HG,43%%3FE%</5:I6J-6H*FTV!B:O5*Q%,H.NUV"8MXR'A8B.0(V8
MQT:P:D3;M6C5!,"D(0H``!R5*JZV`]0N"\I99F=AL)Y,S7IKG^QG6<6C(FMM
MP-4V5R?.%2*N)&XTY9%>#EGKE0HF7.A]F+Q0YCN?.<PB,4Y9J*+I,%ZAYFQ7
M3&=PV:W^V^V<1P_D6K94H52MLM1JW4F-RJ$FA)Q3Z4C8JL/7$D3O1\:G8LW5
M%$YB@H4##Q3FE,:K/.VGKAKVTV=L<[%L-B-@=?<GXRQY,XUK\]@Z?K,`[&!G
MY5[)RAEG<S69MX5R[!^=!0"*%3,CT_+W!W<$50BJPT3U3Y-*NU7_`+U;V4F^
MV>LW9DAR]313<%:N4G!FJY1H`@9LZ*GXU"_SB&$.*>)2BF-=M-:+>=S\*[M2
M%LN;._80QC>\70-08K0P4F9B;Z#TKZ3FT5XE:;-*,"R"G@%!XBEU[>XAN@]9
M\5*D3DO'=1R[CV[8MOL2C.4K(57FZ?:(E<"B1["6"/7C7Z1#&*?PK@@X$R2@
M!W)*@4Y>AB@/"*J3&_IBQ+C3"&R&#XS8;8R3C=EH#%-0LUQE)VFC=:S3\2R2
M*T-7JQ)-:<W:D:RD"D,0[,Z0<",><2)@0>@A%%%,%<ER5*<(G"*IWVUZL_UT
MX-)F"IQGW.3L!-Y.QM4VR!3O+%CQ<B2UXKAA(F*RYV;1H63:%[N@+-#%`.JP
M\O'9VLOT^^%G(XBUF</4\?)/[WR3SPY+`/?_`&)'N7;#M?LV`ZOIS"XD#S/M
M\WM-!4^SQD;P`]I3Y16KBU71=(IN$3$,FJ0AR'*("4Q#@!BF`0^!ZAS-Q<7M
M$@\S7"J\^""QQ:[,+V#"`!]0']@?CR&M+STT.*CJ"[)0\?VG+E_H^(J,CYK9
MDBPLJU%B8ASI1R3LPGE)QX!`$2Q\!%)+/%S#\`FB/XB'.OJ-S;V]M)J%TZC8
M6FE,\/CR'BJWMO1+W<.M6^C:>SJNKF9K&C&E7',\FMQ+CP:"5N[88Q/5<&8K
MHF)*4V*VK=#KD?`,!\9$UGJC5(!?2SWQAVJ2,Q('5=.3_(G76,8?KS774+V7
M4;V6]F^\D>3Z!P'J%`O4W;&@6FUM`M=`LL8+:(-KQ<[-[SXO<2X\!6@P`63N
M=-5Y.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%QK
M(I.$E4%TTUD%DSHK(JD*HDJDH42*)J)G`2G3.0P@("`@(#R02TU&!"X/8R5A
MCD`=&X$$'$$'`@CB"%J>[->LW8VB9WO\9@+"=@R'AB7D/Z4T:4A)RG,T8!K/
M&5=OJ4X:S]FB9$@UF0\J+<WC,F=F*(]PF[@#,NB;ST\Z:R&^E$=P,\#GQ.61
MS\*T6@^^^PN[(-RW/Y8LWW&C.?U1.!;@UV(8:N!K&:LQ&(`=Q6#0T$WH'_ZK
M7L/_`#)C,!_D_P"W/*H=W:&!47+3ZC\2L[^QO<S^F2_#']=6[>J/1K(&'YZ\
MYVS_`$1Q2\@G*I1\:5B7?0LG)P-:432<6>S+*04C+Q[=U9G/B:(`"XK$:-E.
MX"@OTY8N\MQVNI,9:Z<XF$BKZ95'R1^D_N\<MC.PW:;5-JW<^XMSP^RU%H,4
M#"02T.'VDF!(%11C>-.O('&\+F/UM`G")PB<(G")PB<(G")PB<(G")PB<(G"
1)PB<(G")PB<(G")PB<(O_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
